Obsidian Therapeutics (OBX) Stock Price, News & Analysis

Company Overview

Obsidian Therapeutics is a biotechnology company focused on developing engineered cell and gene therapies for serious diseases. Its research centers on technologies designed to control the activity, timing and location of therapeutic proteins within engineered cells.

The company’s CytoDRiVE platform is intended to enable small-molecule regulation of protein expression, which may help improve the safety and effectiveness of cell therapies. Obsidian has applied this technology to immune-cell therapies, including programs designed to support the treatment of solid tumors, as well as to other therapeutic protein and gene-modulation applications.

Obsidian Therapeutics is based in the United States and has operated as a privately held biotechnology company, according to available company information. I could not reliably verify a Nasdaq listing for the symbol “OBX” or confirm current leadership details, so those details are not included.

Key Stats

• Today's Range: $12.25 to $13.95
• 50-Day Range: $12.24 to $35.00
• 52-Week Range: $12.07 to $49.97
• Volume: 532,198 shs
• Average Volume: 727,398 shs
• Market Capitalization: $803.01 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $39.00
• Consensus Rating: Moderate Buy

Obsidian Therapeutics Stock Analysis - MarketRank™

Obsidian Therapeutics scored higher than 68% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Obsidian Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.71, and is based on 1 strong buy rating, 4 buy ratings, 1 hold rating, and 1 sell rating.

Upside Potential

Obsidian Therapeutics has a consensus price target of $39.00, representing about 200.0% upside from its current price of $13.00.

Amount of Analyst Coverage

Obsidian Therapeutics has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Obsidian Therapeutics are expected to decrease in the coming year, from ($1.81) to ($2.74) per share.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.43% of the float of Obsidian Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Obsidian Therapeutics has a short interest ratio ("days to cover") of 0.87, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Obsidian Therapeutics has recently increased by 249.50%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Obsidian Therapeutics does not currently pay a dividend.

Dividend Growth

Obsidian Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 2.6 / 5
• News Sentiment: 0.20

News Sentiment

Obsidian Therapeutics has a news sentiment score of 0.20. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.54 average news sentiment score of companies.

News Coverage This Week

MarketBeat has tracked 4 news articles for Obsidian Therapeutics this week, compared to 3 articles on an average week.

MarketBeat Follows

2 people have added Obsidian Therapeutics to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: N/A
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Obsidian Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Institutions

Obsidian Therapeutics has minimal institutional ownership at this time.

Company Calendar

• Today: 10/10/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: N/A
• Industry: N/A
• Sub-Industry: N/A
• Current Symbol: NASDAQ:OBX
• CIK: 2130606
• Web: www.obsidiantx.com
• Phone: 781-806-6245
• Fax: N/A
• Employees: 87
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Obsidian Therapeutics: $39.00
• High Price Target: $43.00
• Low Price Target: $32.00
• Potential Upside/Downside: +200.0%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.71
• Research Coverage: 7 Analysts

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 4.21
• Quick Ratio: 4.21

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 61,770,000
• Free Float: N/A
• Market Cap: $803.01 million
• Optionable: N/A
• Beta: N/A